

6. Reference List

1. Arizono Y, Yoshikawa H, Naganuma H et al: A mechanism of resistance to TRAIL/Apo2L-induced apoptosis of newly established glioma cell line and sensitisation to TRAIL by genotoxic agents. *Br J Cancer* 2003;88:298-306,
2. Ashkenazi A: Targeting death and decoy receptors of the tumour-necrosis factor superfamily. *Nat Rev Cancer* 2002;2:420-30,
3. Bai J, Sui J, Demirjian A et al: Predominant Bcl-XL knockdown disables antiapoptotic mechanisms: tumor necrosis factor-related apoptosis-inducing ligand-based triple chemotherapy overcomes chemoresistance in pancreatic cancer cells in vitro. *Cancer Res* 2005;65:2344-52,
4. Balch CM, Buzaid AC, Soong SJ et al: Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. *J Clin Oncol* 2001;19:3635-48,
5. Bean MA, Bloom BR, Herberman RB et al: Cell-mediated cytotoxicity for bladder carcinoma: evaluation of a workshop. *Cancer Res* 1975;35:2902-13,
6. Bentires-Alj M, Dejardin E, Viatour P et al: Inhibition of the NF-kappa B transcription factor increases Bax expression in cancer cell lines. *Oncogene* 2001;20:2805-13,
7. Bodmer JL, Holler N, Reynard S et al: TRAIL receptor-2 signals apoptosis through FADD and caspase-8. *Nat Cell Biol* 2000;2:241-3,
8. Bosetti C, La Vecchia C, Naldi L et al: Mortality from cutaneous malignant melanoma in Europe. Has the epidemic levelled off? *Melanoma Res* 2004;14:301-9,
9. Bouralexis S, Findlay DM, Atkins GJ et al: Progressive resistance of BTK-143 osteosarcoma cells to Apo2L/TRAIL-induced apoptosis is mediated by acquisition of DcR2/TRAIL-R4 expression: resensitisation with chemotherapy. *Br J Cancer* 2003;89:206-14,
10. Bouralexis S, Findlay DM, Evdokiou A: Death to the bad guys: targeting cancer via Apo2L/TRAIL. *Apoptosis* 2005;10:35-51,
11. Breslow A: Tumor thickness in evaluating prognosis of cutaneous melanoma. *Ann Surg* 1978;187:440,
12. Brochez L, Naeyaert JM: Understanding the trends in melanoma incidence and mortality: where do we stand? *Eur J Dermatol* 2000;10:71-5,
13. Bruggen J, Fogh J, Sorg C: Tumor production in the nude mouse, fibrinolytic activity and cross-reactivity with antimelanoma sera of various human tumor cell lines. *J Cancer Res Clin Oncol* 1981;102:141-52,
14. Bullani RR, Huard B, Viard-Leveugle I et al: Selective expression of FLIP in malignant melanocytic skin lesions. *J Invest Dermatol* 2001;117:360-4,

15. Carey TE, Takahashi T, Resnick LA, Oettgen HF, Old LJ: Cell surface antigens of human malignant melanoma: mixed hemadsorption assays for humoral immunity to cultured autologous melanoma cells. *Proc Natl Acad Sci U S A* 1976;73:3278-82,
16. Chaudhary PM, Eby M, Jasmin A et al: Death receptor 5, a new member of the TNFR family, and DR4 induce FADD-dependent apoptosis and activate the NF-kappaB pathway. *Immunity* 1997;7:821-30,
17. Chawla-Sarkar M, Bae SI, Reu FJ et al: Downregulation of Bcl-2, FLIP or IAPs (XIAP and survivin) by siRNAs sensitizes resistant melanoma cells to Apo2L/TRAIL-induced apoptosis. *Cell Death Differ* 2004;11:915-23,
18. Chawla-Sarkar M, Bauer JA, Lupica JA et al: Suppression of NF-kappa B survival signaling by nitrosylcobalamin sensitizes neoplasms to the anti-tumor effects of Apo2L/TRAIL. *J Biol Chem* 2003;278:39461-9,
19. Chawla-Sarkar M, Leaman DW, Jacobs BS, Borden EC: IFN-beta pretreatment sensitizes human melanoma cells to TRAIL/Apo2 ligand-induced apoptosis. *J Immunol* 2002;169:847-55,
20. Chen C, Edelstein LC, Gelinas C: The Rel/NF-kappaB family directly activates expression of the apoptosis inhibitor Bcl-x(L). *Mol Cell Biol* 2000;20:2687-95,
21. Chen X, Kandasamy K, Srivastava RK: Differential roles of RelA (p65) and c-Rel subunits of nuclear factor kappa B in tumor necrosis factor-related apoptosis-inducing ligand signaling. *Cancer Res* 2003;63:1059-66,
22. Clark WH: Tumour progression and the nature of cancer. *Br J Cancer* 1991;64:631-44,
23. Clark WH, Jr., Elder DE, Guerry D et al: A study of tumor progression: the precursor lesions of superficial spreading and nodular melanoma. *Hum Pathol* 1984;15:1147-65,
24. Daniels RA, Turley H, Kimberley FC et al: Expression of TRAIL and TRAIL receptors in normal and malignant tissues. *Cell Res* 2005;15:430-8,
25. de Stanchina E, Querido E, Narita M et al: PML is a direct p53 target that modulates p53 effector functions. *Mol Cell* 2004;13:523-35,
26. de Vries E, Coebergh JW: Cutaneous malignant melanoma in Europe. *Eur J Cancer* 2004;40:2355-66,
27. Degtarev A, Boyce M, Yuan J: A decade of caspases. *Oncogene* 2003;22:8543-67,
28. Deveraux QL, Leo E, Stennicke HR et al: Cleavage of human inhibitor of apoptosis protein XIAP results in fragments with distinct specificities for caspases. *EMBO J* 1999;18:5242-51,
29. Di Pietro R, Zauli G: Emerging non-apoptotic functions of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)/Apo2L. *J Cell Physiol* 2004;201:331-40,

30. Diepgen TL, Mahler V: The epidemiology of skin cancer. *Br J Dermatol* 2002;146 Suppl 61:1-6.:1-6,
31. Dolcet X, Llobet D, Pallares J, Matias-Guiu X: NF- κ B in development and progression of human cancer. *Virchows Arch* 2005;446:475-82,
32. Du C, Fang M, Li Y, Li L, Wang X: Smac, a mitochondrial protein that promotes cytochrome c-dependent caspase activation by eliminating IAP inhibition. *Cell* 2000;102:33-42,
33. Eberle J, Fecker LF, Hossini AM et al: CD95/Fas signaling in human melanoma cells: conditional expression of CD95L/FasL overcomes the intrinsic apoptosis resistance of malignant melanoma and inhibits growth and progression of human melanoma xenotransplants. *Oncogene* 2003;22:9131-41,
34. Eberle J, Weitmann S, Thieck O et al: Downregulation of endothelin B receptor in human melanoma cell lines parallel to differentiation genes. *J Invest Dermatol* 1999;112:925-32,
35. Eggert A, Grotzer MA, Zuzak TJ et al: Resistance to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in neuroblastoma cells correlates with a loss of caspase-8 expression. *Cancer Res* 2001;61:1314-9,
36. Ehrhardt H, Fulda S, Schmid I et al: TRAIL induced survival and proliferation in cancer cells resistant towards TRAIL-induced apoptosis mediated by NF- κ B. *Oncogene* 2003;22:3842-52,
37. Fernandez Y, Verhaegen M, Miller TP et al: Differential regulation of noxa in normal melanocytes and melanoma cells by proteasome inhibition: therapeutic implications. *Cancer Res* 2005;65:6294-304,
38. Fischer U, Schulze-Osthoff K: Apoptosis-based therapies and drug targets. *Cell Death Differ* 2005a;12 Suppl 1:942-61.:942-61,
39. Fischer U, Schulze-Osthoff K: Apoptosis-based therapies and drug targets. *Cell Death Differ* 2005b;.::
40. Fischer U, Schulze-Osthoff K: New approaches and therapeutics targeting apoptosis in disease. *Pharmacol Rev* 2005c;57:187-215,
41. Franco AV, Zhang XD, Van Berkel E et al: The role of NF- κ B in TNF-related apoptosis-inducing ligand (TRAIL)-induced apoptosis of melanoma cells. *J Immunol* 2001;166:5337-45,
42. Fulda S, Debatin KM: Apoptosis signaling in tumor therapy. *Ann N Y Acad Sci* 2004;1028:150-6.:150-6,
43. Fulda S, Kufer MU, Meyer E et al: Sensitization for death receptor- or drug-induced apoptosis by re-expression of caspase-8 through demethylation or gene transfer. *Oncogene* 2001b;20:5865-77,

44. Fulda S, Kufer MU, Meyer E et al: Sensitization for death receptor- or drug-induced apoptosis by re-expression of caspase-8 through demethylation or gene transfer. *Oncogene* 2001a;20:5865-77,
45. Fulda S, Meyer E, Debatin KM: Inhibition of TRAIL-induced apoptosis by Bcl-2 overexpression. *Oncogene* 2002a;21:2283-94,
46. Fulda S, Wick W, Weller M, Debatin KM: Smac agonists sensitize for Apo2L/TRAIL- or anticancer drug-induced apoptosis and induce regression of malignant glioma in vivo. *Nat Med* 2002b;8:808-15,
47. Garbe C, Blum A: Epidemiology of cutaneous melanoma in Germany and worldwide. *Skin Pharmacol Appl Skin Physiol* 2001;14:280-90,
48. Giard DJ, Aaronson SA, Todaro GJ et al: In vitro cultivation of human tumors: establishment of cell lines derived from a series of solid tumors. *J Natl Cancer Inst* 1973;51:1417-23,
49. Green DR, Kroemer G: The pathophysiology of mitochondrial cell death. *Science* 2004;305:626-9,
50. Gressner O, Schilling T, Lorenz K et al: TAp63alpha induces apoptosis by activating signaling via death receptors and mitochondria. *EMBO J* 2005;24:2458-71,
51. Griffith TS, Rauch CT, Smolak PJ et al: Functional analysis of TRAIL receptors using monoclonal antibodies. *J Immunol* 1999;162:2597-605,
52. Gudkov AV, Komarova EA: The role of p53 in determining sensitivity to radiotherapy. *Nat Rev Cancer* 2003;3:117-29,
53. Han Z, Hendrickson EA, Bremner TA, Wyche JH: A sequential two-step mechanism for the production of the mature p17:p12 form of caspase-3 in vitro. *J Biol Chem* 1997;272:13432-6,
54. Harper N, Farrow SN, Kaptein A, Cohen GM, MacFarlane M: Modulation of tumor necrosis factor apoptosis-inducing ligand- induced NF-kappa B activation by inhibition of apical caspases. *J Biol Chem* 2001;276:34743-52,
55. Hegde R, Srinivasula SM, Datta P et al: The polypeptide chain-releasing factor GSPT1/eRF3 is proteolytically processed into an IAP-binding protein. *J Biol Chem* 2003;278:38699-706,
56. Hengartner MO: The biochemistry of apoptosis. *Nature* 2000;407:770-6,
57. Hersey P, Zhang XD: How melanoma cells evade trail-induced apoptosis. *Nat Rev Cancer* 2001;1:142-50,
58. Higuchi H, Bronk SF, Takikawa Y et al: The bile acid glycochenodeoxycholate induces trail-receptor 2/DR5 expression and apoptosis. *J Biol Chem* 2001;276:38610-8,

59. Hinz S, Trauzold A, Boenicke L et al: Bcl-XL protects pancreatic adenocarcinoma cells against CD95- and TRAIL-receptor-mediated apoptosis. *Oncogene* 2000;19:5477-86,
60. Holzmann B, Lehmann JM, Ziegler-Heitbrock HW et al: Glycoprotein P3.58, associated with tumor progression in malignant melanoma, is a novel leukocyte activation antigen. *Int J Cancer* 1988;41:542-7,
61. Hossini AM, Eberle J, Fecker LF, Orfanos CE, Geilen CC: Conditional expression of exogenous Bcl-X(S) triggers apoptosis in human melanoma cells in vitro and delays growth of melanoma xenografts. *FEBS Lett* 2003;553:250-6,
62. Hu WH, Johnson H, Shu HB: Tumor necrosis factor-related apoptosis-inducing ligand receptors signal NF-kappaB and JNK activation and apoptosis through distinct pathways. *J Biol Chem* 1999;274:30603-10,
63. Hussein MR, Haemel AK, Wood GS: Apoptosis and melanoma: molecular mechanisms. *J Pathol* 2003;199:275-88,
64. Ichikawa K, Liu W, Fleck M et al: TRAIL-R2 (DR5) mediates apoptosis of synovial fibroblasts in rheumatoid arthritis. *J Immunol* 2003;171:1061-9,
65. Igney FH, Krammer PH: Death and anti-death: tumour resistance to apoptosis. *Nat Rev Cancer* 2002;2:277-88,
66. Irusta PM, Chen YB, Hardwick JM: Viral modulators of cell death provide new links to old pathways. *Curr Opin Cell Biol* 2003;15:700-5,
67. Ishimura N, Isomoto H, Bronk SF, Gores GJ: Trail induces cell migration and invasion in apoptosis-resistant cholangiocarcinoma cells. *Am J Physiol Gastrointest Liver Physiol* 2006;290:G129-G136,
68. Ivanov VN, Bhoumik A, Ronai Z: Death receptors and melanoma resistance to apoptosis. *Oncogene* 2003;22:3152-61,
69. Jin Z, El Deiry WS: Overview of cell death signaling pathways. *Cancer Biol Ther* 2005;4:139-63,
70. Jin Z, McDonald ER, III, Dicker DT, El Deiry WS: Deficient tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) death receptor transport to the cell surface in human colon cancer cells selected for resistance to TRAIL-induced apoptosis. *J Biol Chem* 2004b;279:35829-39,
71. Jin Z, McDonald ER, III, Dicker DT, El Deiry WS: Deficient tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) death receptor transport to the cell surface in human colon cancer cells selected for resistance to TRAIL-induced apoptosis. *J Biol Chem* 2004a;279:35829-39,
72. Jones DT, Ganeshaguru K, Mitchell WA et al: Cytotoxic drugs enhance the ex vivo sensitivity of malignant cells from a subset of acute myeloid leukaemia patients to apoptosis induction by tumour necrosis factor receptor-related apoptosis-inducing ligand. *Br J Haematol* 2003;121:713-20,

73. Kandasamy K, Srinivasula SM, Alnemri ES et al: Involvement of proapoptotic molecules Bax and Bak in tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced mitochondrial disruption and apoptosis: differential regulation of cytochrome c and Smac/DIABLO release. *Cancer Res* 2003;63:1712-21,
74. Karacay B, Sanlioglu S, Griffith TS, Sandler A, Bonthius DJ: Inhibition of the NF-kappaB pathway enhances TRAIL-mediated apoptosis in neuroblastoma cells. *Cancer Gene Ther* 2004;11:681-90,
75. Karin M, Ben Neriah Y: Phosphorylation meets ubiquitination: the control of NF-[kappa]B activity. *Annu Rev Immunol* 2000;18:621-63.:621-63,
76. Karin M, Greten FR: NF-kappaB: linking inflammation and immunity to cancer development and progression. *Nat Rev Immunol* 2005;5:749-59,
77. Karin M, Lin A: NF-kappaB at the crossroads of life and death. *Nat Immunol* 2002;3:221-7,
78. Kazhdan I, Marciniak RA: Death receptor 4 (DR4) efficiently kills breast cancer cells irrespective of their sensitivity to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL). *Cancer Gene Ther* 2004;11:691-8,
79. Keilholz U, Gore ME: Biochemotherapy for advanced melanoma. *Semin Oncol* 2002;29:456-61,
80. Keilholz U, Punt CJ, Gore M et al: Dacarbazine, cisplatin, and interferon-alfa-2b with or without interleukin-2 in metastatic melanoma: a randomized phase III trial (18951) of the European Organisation for Research and Treatment of Cancer Melanoma Group. *J Clin Oncol* 2005;23:6747-55,
81. Kelley RF, Totpal K, Lindstrom SH et al: Receptor-selective Mutants of Apoptosis-inducing Ligand 2/Tumor Necrosis Factor-related Apoptosis-inducing Ligand Reveal a Greater Contribution of Death Receptor (DR) 5 than DR4 to Apoptosis Signaling. *J Biol Chem* 2005;280:2205-12,
82. Kelley SK, Ashkenazi A: Targeting death receptors in cancer with Apo2L/TRAIL. *Curr Opin Pharmacol* 2004;4:333-9,
83. Kelley SK, Harris LA, Xie D et al: Preclinical studies to predict the disposition of Apo2L/tumor necrosis factor-related apoptosis-inducing ligand in humans: characterization of in vivo efficacy, pharmacokinetics, and safety. *J Pharmacol Exp Ther* 2001;299:31-8,
84. Kerr JF, Wyllie AH, Currie AR: Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics. *Br J Cancer* 1972;26:239-57,
85. Kim EH, Kim SU, Choi KS: Rottlerin sensitizes glioma cells to TRAIL-induced apoptosis by inhibition of Cdc2 and the subsequent downregulation of survivin and XIAP. *Oncogene* 2005a;24:838-49,
86. Kim HS, Chang I, Kim JY, Choi KH, Lee MS: Caspase-mediated p65 cleavage promotes TRAIL-induced apoptosis. *Cancer Res* 2005b;65:6111-9,

87. Kim K, Fisher MJ, Xu SQ, El Deiry WS: Molecular determinants of response to TRAIL in killing of normal and cancer cells. *Clin Cancer Res* 2000;6:335-46,
88. Kim YS, Schwabe RF, Qian T, Lemasters JJ, Brenner DA: TRAIL-mediated apoptosis requires NF-kappaB inhibition and the mitochondrial permeability transition in human hepatoma cells. *Hepatology* 2002;36:1498-508,
89. Kischkel FC, Lawrence DA, Tinel A et al: Death receptor recruitment of endogenous caspase-10 and apoptosis initiation in the absence of caspase-8. *J Biol Chem* 2001;276:46639-46,
90. Koenig U, Eckhart L, Tschachler E: Evidence that caspase-13 is not a human but a bovine gene. *Biochem Biophys Res Commun* 2001;285:1150-4,
91. Koornstra JJ, Kleibeuker JH, van Geelen CM et al: Expression of TRAIL (TNF-related apoptosis-inducing ligand) and its receptors in normal colonic mucosa, adenomas, and carcinomas. *J Pathol* 2003;200:327-35,
92. Kreuz S, Siegmund D, Scheurich P, Wajant H: NF-kappaB inducers upregulate cFLIP, a cycloheximide-sensitive inhibitor of death receptor signaling. *Mol Cell Biol* 2001;21:3964-73,
93. Krueger A, Baumann S, Krammer PH, Kirchhoff S: FLICE-inhibitory proteins: regulators of death receptor-mediated apoptosis. *Mol Cell Biol* 2001;21:8247-54,
94. LeBlanc AC: Natural cellular inhibitors of caspases. *Prog Neuropsychopharmacol Biol Psychiatry* 2003;27:215-29,
95. LeBlanc HN, Ashkenazi A: Apo2L/TRAIL and its death and decoy receptors. *Cell Death Differ* 2003;10:66-75,
96. Lee DY, Lee MW, Lee HJ et al: ERK1/2 activation attenuates TRAIL-induced apoptosis through the regulation of mitochondria-dependent pathway. *Toxicol In Vitro* 2006;::
97. Leist M, Jaattela M: Four deaths and a funeral: from caspases to alternative mechanisms. *Nat Rev Mol Cell Biol* 2001;2:589-98,
98. Lens MB, Dawes M: Global perspectives of contemporary epidemiological trends of cutaneous malignant melanoma. *Br J Dermatol* 2004;150:179-85,
99. Leverkus M, Sprick MR, Wachter T et al: TRAIL-induced apoptosis and gene induction in HaCaT keratinocytes: differential contribution of TRAIL receptors 1 and 2. *J Invest Dermatol* 2003;121:149-55,
100. Li-Weber M, Krammer PH: Function and regulation of the CD95 (APO-1/Fas) ligand in the immune system. *Semin Immunol* 2003;15:145-57,
101. Liabakk NB, Sundan A, Torp S et al: Development, characterization and use of monoclonal antibodies against sTRAIL: measurement of sTRAIL by ELISA. *J Immunol Methods* 2002;259:119-28,

102. Lichtenstein DL, Doronin K, Toth K et al: Adenovirus E3-6.7K protein is required in conjunction with the E3-RID protein complex for the internalization and degradation of TRAIL receptor 2. *J Virol* 2004;78:12297-307,
103. Liu QA, Hengartner MO: The molecular mechanism of programmed cell death in *C. elegans*. *Ann N Y Acad Sci* 1999;887:92-104.:92-104,
104. Liu X, Kim CN, Yang J, Jemmerson R, Wang X: Induction of apoptotic program in cell-free extracts: requirement for dATP and cytochrome c. *Cell* 1996;86:147-57,
105. Liu X, Yue P, Khuri FR, Sun SY: p53 upregulates death receptor 4 expression through an intronic p53 binding site. *Cancer Res* 2004;64:5078-83,
106. MacFarlane M: TRAIL-induced signalling and apoptosis. *Toxicol Lett* 2003;139:89-97,
107. MacFarlane M, Kohlhaas SL, Sutcliffe MJ, Dyer MJ, Cohen GM: TRAIL receptor-selective mutants signal to apoptosis via TRAIL-R1 in primary lymphoid malignancies. *Cancer Res* 2005;65:11265-70,
108. Mashima T, Naito M, Fujita N, Noguchi K, Tsuruo T: Identification of actin as a substrate of ICE and an ICE-like protease and involvement of an ICE-like protease but not ICE in VP-16-induced U937 apoptosis. *Biochem Biophys Res Commun* 1995;217:1185-92,
109. Matysiak M, Jurewicz A, Jaskolski D, Selmaj K: TRAIL induces death of human oligodendrocytes isolated from adult brain. *Brain* 2002;125:2469-80,
110. Meek DW: The p53 response to DNA damage. *DNA Repair (Amst)* 2004;3:1049-56,
111. Megahed M, Schon M, Selimovic D, Schon MP: Reliability of diagnosis of melanoma in situ. *Lancet* 2002;359:1921-2,
112. Miao L, Yi P, Wang Y, Wu M: Etoposide upregulates Bax-enhancing tumour necrosis factor-related apoptosis inducing ligand-mediated apoptosis in the human hepatocellular carcinoma cell line QGY-7703. *Eur J Biochem* 2003;270:2721-31,
113. Mitsiades CS, Treon SP, Mitsiades N et al: TRAIL/Apo2L ligand selectively induces apoptosis and overcomes drug resistance in multiple myeloma: therapeutic applications. *Blood* 2001a;98:795-804,
114. Mitsiades N, Poulaki V, Mitsiades C, Tsokos M: Ewing's sarcoma family tumors are sensitive to tumor necrosis factor-related apoptosis-inducing ligand and express death receptor 4 and death receptor 5. *Cancer Res* 2001b;61:2704-12,
115. Naka T, Sugamura K, Hylander BL et al: Effects of tumor necrosis factor-related apoptosis-inducing ligand alone and in combination with chemotherapeutic agents on patients' colon tumors grown in SCID mice. *Cancer Res* 2002b;62:5800-6,

116. Naka T, Sugamura K, Hylander BL et al: Effects of tumor necrosis factor-related apoptosis-inducing ligand alone and in combination with chemotherapeutic agents on patients' colon tumors grown in SCID mice. *Cancer Res* 2002a;62:5800-6,
117. Ng CP, Zisman A, Bonavida B: Synergy is achieved by complementation with Apo2L/TRAIL and actinomycin D in Apo2L/TRAIL-mediated apoptosis of prostate cancer cells: role of XIAP in resistance. *Prostate* 2002;53:286-99,
118. Nguyen T, Zhang XD, Hersey P: Relative resistance of fresh isolates of melanoma to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis. *Clin Cancer Res* 2001;7:966s-73s,
119. Nimmanapalli R, Porosnicu M, Nguyen D et al: Cotreatment with STI-571 enhances tumor necrosis factor alpha-related apoptosis-inducing ligand (TRAIL or apo-2L)-induced apoptosis of Bcr-Abl-positive human acute leukemia cells. *Clin Cancer Res* 2001;7:350-7,
120. Nyormoi O, Mills L, Bar-Eli M: An MMP-2/MMP-9 inhibitor, 5a, enhances apoptosis induced by ligands of the TNF receptor superfamily in cancer cells. *Cell Death Differ* 2003;10:558-69,
121. Okano H, Shiraki K, Inoue H et al: Cellular FLICE/caspase-8-inhibitory protein as a principal regulator of cell death and survival in human hepatocellular carcinoma. *Lab Invest* 2003;83:1033-43,
122. Orth K, Chinnaiyan AM, Garg M, Froelich CJ, Dixit VM: The CED-3/ICE-like protease Mch2 is activated during apoptosis and cleaves the death substrate lamin A. *J Biol Chem* 1996;271:16443-6,
123. Pan G, O'Rourke K, Chinnaiyan AM et al: The receptor for the cytotoxic ligand TRAIL. *Science* 1997;276:111-3,
124. Petak I, Douglas L, Tillman DM, Vernes R, Houghton JA: Pediatric rhabdomyosarcoma cell lines are resistant to Fas-induced apoptosis and highly sensitive to TRAIL-induced apoptosis. *Clin Cancer Res* 2000;6:4119-27,
125. Pistritto G, Jost M, Srinivasula SM et al: Expression and transcriptional regulation of caspase-14 in simple and complex epithelia. *Cell Death Differ* 2002;9:995-1006,
126. Pitti RM, Marsters SA, Ruppert S et al: Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family. *J Biol Chem* 1996;271:12687-90,
127. Prindull G: Apoptosis in the embryo and tumorigenesis. *Eur J Cancer* 1995;31A:116-23,
128. Raisova M, Hossini AM, Eberle J et al: The Bax/Bcl-2 ratio determines the susceptibility of human melanoma cells to CD95/Fas-mediated apoptosis. *J Invest Dermatol* 2001;117:333-40,

129. Ramp U, Caliskan E, Mahotka C et al: Apoptosis induction in renal cell carcinoma by TRAIL and gamma-radiation is impaired by deficient caspase-9 cleavage. *Br J Cancer* 2003;88:1800-7,
130. Ravi R, Bedi A: NF-kappaB in cancer--a friend turned foe. *Drug Resist Updat* 2004;7:53-67,
131. Ravi R, Bedi GC, Engstrom LW et al: Regulation of death receptor expression and TRAIL/Apo2L-induced apoptosis by NF-kappaB. *Nat Cell Biol* 2001;3:409-16,
132. Ray S, Almasan A: Apoptosis induction in prostate cancer cells and xenografts by combined treatment with Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand and CPT-11. *Cancer Res* 2003;63:4713-23,
133. Rigel DS: The effect of sunscreen on melanoma risk. *Dermatol Clin* 2002;20:601-6,
134. Rockmann H, Schadendorf D: Drug resistance in human melanoma: mechanisms and therapeutic opportunities. *Onkologie* 2003;26:581-7,
135. Rofstad EK, Halsor EF: Vascular endothelial growth factor, interleukin 8, platelet-derived endothelial cell growth factor, and basic fibroblast growth factor promote angiogenesis and metastasis in human melanoma xenografts. *Cancer Res* 2000;60:4932-8,
136. Roth W, Isenmann S, Naumann U et al: Locoregional Apo2L/TRAIL eradicates intracranial human malignant glioma xenografts in athymic mice in the absence of neurotoxicity. *Biochem Biophys Res Commun* 1999;265:479-83,
137. Ryu HS, Chang KH, Chang SJ et al: Expression of TRAIL (TNF-related apoptosis-inducing ligand) receptors in cervical cancer. *Int J Gynecol Cancer* 2000;10:417-24,
138. Sakahira H, Enari M, Nagata S: Cleavage of CAD inhibitor in CAD activation and DNA degradation during apoptosis. *Nature* 1998;391:96-9,
139. Savill J, Fadok V: Corpse clearance defines the meaning of cell death. *Nature* 2000;407:784-8,
140. Sayers TJ, Brooks AD, Koh CY et al: The proteasome inhibitor PS-341 sensitizes neoplastic cells to TRAIL-mediated apoptosis by reducing levels of c-FLIP. *Blood* 2003;102:303-10,
141. Schmitz I, Kirchhoff S, Krammer PH: Regulation of death receptor-mediated apoptosis pathways. *Int J Biochem Cell Biol* 2000;32:1123-36,
142. Schuler M, Green DR: Transcription, apoptosis and p53: catch-22. *Trends Genet* 2005;21:182-7,
143. Screaton GR, Mongkolsapaya J, Xu XN et al: TRICK2, a new alternatively spliced receptor that transduces the cytotoxic signal from TRAIL. *Curr Biol* 1997;7:693-6,

144. Secchiero P, Milani D, Gonelli A et al: Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) and TNF-alpha promote the NF-kappaB-dependent maturation of normal and leukemic myeloid cells. *J Leukoc Biol* 2003;74:223-32,
145. Seol DW, Li J, Seol MH et al: Signaling events triggered by tumor necrosis factor-related apoptosis-inducing ligand (TRAIL): caspase-8 is required for TRAIL-induced apoptosis. *Cancer Res* 2001;61:1138-43,
146. Serrone L, Zeuli M, Sega FM, Cognetti F: Dacarbazine-based chemotherapy for metastatic melanoma: thirty-year experience overview. *J Exp Clin Cancer Res* 2000;19:21-34,
147. Shankar S, Chen X, Srivastava RK: Effects of sequential treatments with chemotherapeutic drugs followed by TRAIL on prostate cancer in vitro and in vivo. *Prostate* 2005;62:165-86,
148. Sheridan JP, Marsters SA, Pitti RM et al: Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors. *Science* 1997;277:818-21,
149. Shetty S, Gladden JB, Henson ES et al: Tumor necrosis factor-related apoptosis inducing ligand (TRAIL) up-regulates death receptor 5 (DR5) mediated by NFkappaB activation in epithelial derived cell lines. *Apoptosis* 2002;7:413-20,
150. Shigeno M, Nakao K, Ichikawa T et al: Interferon-alpha sensitizes human hepatoma cells to TRAIL-induced apoptosis through DR5 upregulation and NF-kappa B inactivation. *Oncogene* 2003;22:1653-62,
151. Singh TR, Shankar S, Chen X, Asim M, Srivastava RK: Synergistic interactions of chemotherapeutic drugs and tumor necrosis factor-related apoptosis-inducing ligand/Apo-2 ligand on apoptosis and on regression of breast carcinoma in vivo. *Cancer Res* 2003;63:5390-400,
152. Soengas MS, Lowe SW: Apoptosis and melanoma chemoresistance. *Oncogene* 2003;22:3138-51,
153. Song JH, Song DK, Herlyn M, Petruk KC, Hao C: Cisplatin down-regulation of cellular Fas-associated death domain-like interleukin-1beta-converting enzyme-like inhibitory proteins to restore tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in human melanoma cells. *Clin Cancer Res* 2003;9:4255-66,
154. Sosman JA, Puzanov I: Molecular targets in melanoma from angiogenesis to apoptosis. *Clin Cancer Res* 2006;12:2376s-83s,
155. Spierings DC, de Vries EG, Timens W et al: Expression of TRAIL and TRAIL death receptors in stage III non-small cell lung cancer tumors. *Clin Cancer Res* 2003;9:3397-405,
156. Sprick MR, Rieser E, Stahl H et al: Caspase-10 is recruited to and activated at the native TRAIL and CD95 death-inducing signalling complexes in a FADD-dependent manner but can not functionally substitute caspase-8. *EMBO J* 2002;21:4520-30,

157. Strater J, Hinz U, Walczak H et al: Expression of TRAIL and TRAIL receptors in colon carcinoma: TRAIL-R1 is an independent prognostic parameter. *Clin Cancer Res* 2002;8:3734-40,
158. Suzuki Y, Imai Y, Nakayama H et al: A serine protease, HtrA2, is released from the mitochondria and interacts with XIAP, inducing cell death. *Mol Cell* 2001a;8:613-21,
159. Suzuki Y, Nakabayashi Y, Takahashi R: Ubiquitin-protein ligase activity of X-linked inhibitor of apoptosis protein promotes proteasomal degradation of caspase-3 and enhances its anti-apoptotic effect in Fas-induced cell death. *Proc Natl Acad Sci U S A* 2001b;98:8662-7,
160. Tepper CG, Seldin MF: Modulation of caspase-8 and FLICE-inhibitory protein expression as a potential mechanism of Epstein-Barr virus tumorigenesis in Burkitt's lymphoma. *Blood* 1999;94:1727-37,
161. Thomas WD, Zhang XD, Franco AV, Nguyen T, Hersey P: TNF-related apoptosis-inducing ligand-induced apoptosis of melanoma is associated with changes in mitochondrial membrane potential and perinuclear clustering of mitochondria. *J Immunol* 2000;165:5612-20,
162. Thompson CB: Apoptosis in the pathogenesis and treatment of disease. *Science* 1995;267:1456-62,
163. Tran SE, Holmstrom TH, Ahonen M, Kahari VM, Eriksson JE: MAPK/ERK overrides the apoptotic signaling from Fas, TNF, and TRAIL receptors. *J Biol Chem* 2001;276:16484-90,
164. Trauzold A, Wermann H, Arlt A et al: CD95 and TRAIL receptor-mediated activation of protein kinase C and NF-kappaB contributes to apoptosis resistance in ductal pancreatic adenocarcinoma cells. *Oncogene* 2001;20:4258-69,
165. Vermeulen K, Van Bockstaele DR, Berneman ZN: Apoptosis: mechanisms and relevance in cancer. *Ann Hematol* 2005a;84:627-39,
166. Vermeulen K, Van Bockstaele DR, Berneman ZN: Apoptosis: mechanisms and relevance in cancer. *Ann Hematol* 2005b;84:627-39,
167. Vijuk G, Coates AS: Survival of patients with visceral metastatic melanoma from an occult primary lesion: a retrospective matched cohort study. *Ann Oncol* 1998;9:419-22,
168. Voorhees PM, Dees EC, O'Neil B, Orlowski RZ: The proteasome as a target for cancer therapy. *Clin Cancer Res* 2003;9:6316-25,
169. Vousden KH, Lu X: Live or let die: the cell's response to p53. *Nat Rev Cancer* 2002;2:594-604,
170. Walczak H, Miller RE, Ariail K et al: Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. *Nat Med* 1999;5:157-63,

171. Wang S, El Deiry WS: TRAIL and apoptosis induction by TNF-family death receptors. *Oncogene* 2003;22:8628-33,
172. Wang X: The expanding role of mitochondria in apoptosis. *Genes Dev* 2001;15:2922-33,
173. Wiley SR, Schooley K, Smolak PJ et al: Identification and characterization of a new member of the TNF family that induces apoptosis. *Immunity* 1995;3:673-82,
174. Wu JJ, Zhang XD, Gillespie S, Hersey P: Selection for TRAIL resistance results in melanoma cells with high proliferative potential. *FEBS Lett* 2005;579:1940-4,
175. Yagita H, Takeda K, Hayakawa Y, Smyth MJ, Okumura K: TRAIL and its receptors as targets for cancer therapy. *Cancer Sci* 2004;95:777-83,
176. Yang X, Merchant MS, Romero ME et al: Induction of caspase 8 by interferon gamma renders some neuroblastoma (NB) cells sensitive to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) but reveals that a lack of membrane TR1/TR2 also contributes to TRAIL resistance in NB. *Cancer Res* 2003;63:1122-9,
177. Zauli G, Sancilio S, Cataldi A et al: PI-3K/Akt and NF-kappaB/IkappaBalpha pathways are activated in Jurkat T cells in response to TRAIL treatment. *J Cell Physiol* 2005;202:900-11,
178. Zeise E, Weichenthal M, Schwarz T, Kulms D: Resistance of human melanoma cells against the death ligand TRAIL is reversed by ultraviolet-B radiation via downregulation of FLIP. *J Invest Dermatol* 2004;123:746-54,
179. Zhang L, Fang B: Mechanisms of resistance to TRAIL-induced apoptosis in cancer. *Cancer Gene Ther* 2004;:
180. Zhang X, Jin TG, Yang H et al: Persistent c-FLIP(L) expression is necessary and sufficient to maintain resistance to tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in prostate cancer. *Cancer Res* 2004a;64:7086-91,
181. Zhang XD, Borrow JM, Zhang XY, Nguyen T, Hersey P: Activation of ERK1/2 protects melanoma cells from TRAIL-induced apoptosis by inhibiting Smac/DIABLO release from mitochondria. *Oncogene* 2003a;22:2869-81,
182. Zhang XD, Borrow JM, Zhang XY, Nguyen T, Hersey P: Activation of ERK1/2 protects melanoma cells from TRAIL-induced apoptosis by inhibiting Smac/DIABLO release from mitochondria. *Oncogene* 2003b;22:2869-81,
183. Zhang XD, Franco A, Myers K et al: Relation of TNF-related apoptosis-inducing ligand (TRAIL) receptor and FLICE-inhibitory protein expression to TRAIL-induced apoptosis of melanoma. *Cancer Res* 1999;59:2747-53,
184. Zhang XD, Franco AV, Nguyen T, Gray CP, Hersey P: Differential localization and regulation of death and decoy receptors for TNF-related apoptosis-inducing ligand (TRAIL) in human melanoma cells. *J Immunol* 2000a;164:3961-70,

185. Zhang XD, Nguyen T, Thomas WD, Sanders JE, Hersey P: Mechanisms of resistance of normal cells to TRAIL induced apoptosis vary between different cell types. *FEBS Lett* 2000b;482:193-9,
186. Zhang XD, Wu JJ, Gillespie S, Borrow J, Hersey P: Human melanoma cells selected for resistance to apoptosis by prolonged exposure to tumor necrosis factor-related apoptosis-inducing ligand are more vulnerable to necrotic cell death induced by Cisplatin. *Clin Cancer Res* 2006;12:1355-64,
187. Zhang XD, Zhang XY, Gray CP, Nguyen T, Hersey P: Tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis of human melanoma is regulated by smac/DIABLO release from mitochondria. *Cancer Res* 2001;61:7339-48,
188. Zhang XY, Zhang XD, Borrow JM, Nguyen T, Hersey P: Translational control of tumor necrosis factor-related apoptosis-inducing ligand death receptor expression in melanoma cells. *J Biol Chem* 2004b;279:10606-14,
189. Zou H, Henzel WJ, Liu X, Lutschg A, Wang X: Apaf-1, a human protein homologous to *C. elegans* CED-4, participates in cytochrome c-dependent activation of caspase-3. *Cell* 1997;90:405-13,